Methods of, inter alia, detecting the presence of one or more analytes in one or more query samples include providing one or more sensor that each include biomolecules disposed on a functionalized surface of one or more giant magnetoresistance (GMR) sensors. Modes of operation remove or add magnetic beads from the vicinity of sensor surfaces by interactions with the biomolecules. The methods feature, inter alia, detecting the presence of one or more analytes in one or more query samples by measuring magnetoresistance change of the one or more GMR sensors based on determining magnetoresistance before and after passing magnetic particles over the one or more sensors.

Devices and methods for conducting lateral flow immunochromatographic assays may be used, in some aspects, to measure the level of glutathione-S-transferase pi in a biological fluid collected from a human subject suspected of having had a stroke in order to determine whether the subject has had a stroke or to aid in the selection and administration of a treatment for the suspected stroke. In other aspects, such devices may be used to diagnose, monitor, and/or treat acute respiratory distress syndromes (ARDS), such as the novel coronavirus designated COVID-19.

Methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining diabetic nephropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.

A method including detecting a presence of at least one analyte in a sample from a subject wherein the at least one analyte is selected from the group consisting of: mesothelin, Galectin-3-binding protein, Clusterin, Polymeric immunoglobulin receptor, Neutrophil gelatinase-associated lipocalin, Leucine-rich alpha-2-glycoprotein, Osteopontin, Alpha-amylase 1, WAP four-disulfide core domain protein 2, Mucin-16, GSTP1, PRDX5, TXN, PRDX6, and SOD1, and determining the subject has hydrosalpinx if the sample comprises an increased level of mesothelin, Galectin-3-binding protein, Clusterin, Polymeric immunoglobulin receptor, Neutrophil gelatinase-associated lipocalin, Leucine-rich alpha-2-glycoprotein, Osteopontin, Alpha-amylase 1, WAP four-disulfide core domain protein 2, and/or Mucin-16 relative to a control, and/or a decreased level of GSTP1, PRDX5, TXN, PRDX6, and/or SOD1, relative to the control, is provided herein. The method may further include if the subject is determined to have hydrosalpinx, administering a hydrosalpinx therapy to the subject.

The present invention is directed to fluorescent molecular sensor based on Thiazole Orange for protein detection. interaction of the protein target with the molecular sensors of this invention results in a significant increase in the fluorescence emission. The generation of light output signal enables one to detect protein biomarkers associated with different diseases or detecting the protein of interest also in living cells.

The present invention provides an assay for detection of oxidized glutathione (GSSG).

The present invention relates to methods for the diagnosis and the treatment of cancer, in particular breast cancer. In particular, the present invention relates to a method of diagnosing cancer in a subject comprising the steps of i) determining the expression level of hGSTA1 in a tumor sample obtained from the subject, ii) comparing the expression level determined at step i) with its predetermined reference value and ii) concluding that the subject suffers from a cancer when the expression level of hGSTA1 is lower than its predetermined reference value.

Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes described specifically label only their target active enzymes involved in xenobiotic metabolism and therefore provide a measurement of true protein functional activity rather than transcript or protein abundance. The activity-based probes also provide multimodal profiling of these active enzymes. Methods for preparing the activity based probes and exemplary methods for their use also are disclosed.

The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection. The invention also relates to methods of treating the individual diagnosed with a traumatic brain injury (TBI) or a mild traumatic brain injury (mTBI) using such biomarkers.

Process for in vitro diagnosis and/or monitoring and/or prognosis and/or theranosis of hepatic disorders from a biological sample originating from a subject, in which process the presence and/or the concentration of the marker ADH1B (SEQ ID NO.2) and/or the presence and/or the concentration of the combination of the markers ADH1B (SEQ ID NO.2) and ADH1A (SEQ ID NO.1) is determined.